Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess bioequivalence of a potential generic 750 mg
balsalazide disodium capsule formulation compared with Salix Pharmaceutical's 750 mg
balsalazide disodium capsule, Colazal, following a single 750 mg dose, under fasting
conditions.